Skip to main content

Table 3 Prognostic value of combined 5hmC/5caC IHC score in ERG− PC

From: Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

ERG− PC patient subset (n = 150, 64 BCR)
Variable Univariate Multivariatea Multivariateb
HR (95% CI) p value C-index HR (95% CI) p value HR (95% CI) p value C-indexc C-indexd
5hmC/5caC (low vs. moderate) 2.06 (1.14–3.72) 0.017 0.62 1.79 (0.98–3.28) 0.057 0.75
5hmC/5caC (low vs. high) 2.99 (1.49–6.02) 0.002 0.62 2.48 (1.20–5.13) 0.014 3.18 (1.54–6.56) 0.002
Pre-op. PSA (≤ 10 vs. > 10 ng/ml) 2.65 (1.47–4.76) 0.001 0.60 2.79 (1.52–5.12) 0.001 4.22 (1.67–10.65) 0.002 0.69
Gleason score (< 7 vs. ≥ 7) 2.18 (1.27–3.72) 0.005 0.59 1.61 (0.88–2.94) 0.123
Surgical margin (neg. vs. pos.) 2.63 (1.63–4.22) < 0.001 0.61 2.04 (1.17–3.56) 0.012 4.17 (2.02–8.63) < 0.001
Tumor stage (≤pT2c vs. ≥pT3a) 2.55 (1.59–4.11) < 0.001 0.61 1.70 (0.98–2.95) 0.060
  1. Univariate and multivariate Cox regression analyses of time to BCR using a combined 5hmC/5caC IHC score (low: 5hmC ≤ 1 and 5caC ≤ 1; moderate: 5hmC ≤ 1 and 5caC > 1, or 5hmC > 1 and 5caC ≤ 1; high: 5hmC > 1 and 5caC > 1)
  2. Significant p values are highlighted in italics
  3. aGlobal multivariate model including all parameters
  4. bFinal multivariate model including only significant variables
  5. cHarrell’s C-index for final model including 5hmC/5caC
  6. dHarrell’s C-index for final model excluding 5hmC/5caC